Auswahl der wissenschaftlichen Literatur zum Thema „Myeloid leukemia“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Myeloid leukemia" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Myeloid leukemia":
Swatler, Julian, Laura Turos-Korgul, Ewa Kozlowska und Katarzyna Piwocka. „Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias“. Cancers 13, Nr. 6 (10.03.2021): 1203. http://dx.doi.org/10.3390/cancers13061203.
Namikawa, R., R. Ueda und S. Kyoizumi. „Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice“. Blood 82, Nr. 8 (15.10.1993): 2526–36. http://dx.doi.org/10.1182/blood.v82.8.2526.2526.
Namikawa, R., R. Ueda und S. Kyoizumi. „Growth of human myeloid leukemias in the human marrow environment of SCID-hu mice“. Blood 82, Nr. 8 (15.10.1993): 2526–36. http://dx.doi.org/10.1182/blood.v82.8.2526.bloodjournal8282526.
Aue, Georg, Yang Du, Susan M. Cleveland, Stephen B. Smith, Utpal P. Davé, Delong Liu, Marc A. Weniger et al. „Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia“. Blood 118, Nr. 17 (27.10.2011): 4674–81. http://dx.doi.org/10.1182/blood-2011-04-351528.
Shvachko, L. P. „EMT-mechanizm induces the leukemic stemness phenotype in myeloid leukemias“. Faktori eksperimental'noi evolucii organizmiv 23 (09.09.2018): 256–60. http://dx.doi.org/10.7124/feeo.v23.1024.
Jamieson, Catriona, Sidd Jaiswal, David Traver, Jason Gotlib, Mark Chao und Irving L. Weissman. „Increased Expression of CD47 Is a Constant Marker in Mouse and Human Myeloid Leukemias.“ Blood 106, Nr. 11 (16.11.2005): 3260. http://dx.doi.org/10.1182/blood.v106.11.3260.3260.
ENACHE, Tatiana Cristina, Ana-Maria VLĂDĂREANU, Horia BUMBEA, Minodora ONISÂI und Ion DUMITRU. „EPIDEMIOLOGICAL AND IMMUNOPHENOTYPIC CHARACTERIZATION OF ACUTE MYELOID LEUKEMIAS“. Romanian Journal of Medical Practice 12, Nr. 4 (31.12.2017): 234–39. http://dx.doi.org/10.37897/rjmp.2017.4.11.
Войцеховский, Валерий, Valeriy Voytsekhovskiy, Татьяна Заболотских, Tat'yana Zabolotskikh, Алексей Григоренко, Aleksey Grigorenko, Екатерина Филатова und Ekaterina Filatova. „DAMAGE OF THE BRONCHOPULMONARY SYSTEM IN PATIENTS WITH CHRONIC HEMOBLASTOSIS“. Bulletin physiology and pathology of respiration 1, Nr. 69 (05.10.2018): 25–35. http://dx.doi.org/10.12737/article_5b975083a62278.59044240.
Padmanabhan, Dr K. „An Interesting Case of Acute Myeloid Leukemia“. Journal of Medical Science And clinical Research 05, Nr. 02 (28.02.2017): 18166–68. http://dx.doi.org/10.18535/jmscr/v5i2.150.
Jones, Letetia, Sabina Sevcikova, Vernon Phan, Sachi Jain, Angell Shieh, Joshua Dubansky, Min Li et al. „Myc Drives Chromosomal Gain in Acute Myeloid Leukemia“. Blood 112, Nr. 11 (16.11.2008): 792. http://dx.doi.org/10.1182/blood.v112.11.792.792.
Dissertationen zum Thema "Myeloid leukemia":
Cheung, Man-sze, und 張敏思. „Characterization of Leukemic stem cells in acute myeloid Leukemia“. Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2008. http://hub.hku.hk/bib/B40687582.
Cheung, Man-sze. „Characterization of Leukemic stem cells in acute myeloid Leukemia“. Click to view the E-thesis via HKUTO, 2008. http://sunzi.lib.hku.hk/hkuto/record/B40687582.
Yaseen, Mumtaz. „Proteomics of Acute Myeloid Leukemia:“. Diss., lmu, 2007. http://nbn-resolving.de/urn:nbn:de:bvb:19-69882.
Gunnarsson, Niklas. „Chronic myeloid leukemia and cancer“. Doctoral thesis, Umeå universitet, Medicin, 2017. http://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-141144.
VARINELLI, MARCO. „MODELLING CHRONIC MYELOID LEUKEMIA IN ZEBRAFISH“. Doctoral thesis, Università degli studi di Brescia, 2021. http://hdl.handle.net/11379/544088.
Cornforth, Terri Victoria. „Characterising the cell biology of leukemic stem cells in acute myeloid leukemia“. Thesis, University of Oxford, 2013. http://ora.ox.ac.uk/objects/uuid:654b2176-fd50-427e-86f2-74e928054bef.
Zhang, Lu [Verfasser]. „Immunogenicity of leukemia stem cells in acute myeloid leukemia / Lu Zhang“. Ulm : Universität Ulm. Medizinische Fakultät, 2012. http://d-nb.info/1020022574/34.
García, Montolío Marc 1991. „The Role of PHF19 in myeloid leukemia“. Doctoral thesis, Universitat Pompeu Fabra, 2019. http://hdl.handle.net/10803/667911.
El complejo de proteínas Polycomb (PcG), es un grupo de reguladores epigenéticos altamente conservados que participan en distintas funciones biológicas como el desarrollo embrionario, la auto renovación de las células madre, la proliferación y están involucradas también en cáncer. La proteína PHD finger 19 (PHF19), es un factor asociado al complejo represor Polycomb 2 (PRC2). PHF19 ha sido propuesta como reguladora de la actividad de PRC2 en células madre embrionarias. También se ha visto que esta sobreexpressada en diferentes canceres y líneas celulares cancerígenas. Nosotros hemos demostrado que la eliminación de PHF19 disminuye la proliferación de las líneas celulares mieloides cancerígenas. Hemos demostrado que la depleción de PHF19 en las células de leucemia crónica mieloide las induce a diferenciarse hacia eritrocitos. Mecánicamente, hemos demostrado que PHF19 regula la proliferación de esta línea celular mediante su interacción con el regulador de ciclo celular p21. Además, hemos observado que MTF2, un homólogo de PHF19, se deposita en aquellos genes donde previamente estaba PHF19. En conjunto, nuestros resultados muestran que PHF19 es un factor transcripcional clave en líneas celulares mieloides y sugieren que la inhibición de PHF19 podría ser una potencial diana para ser explorada para el tratamiento de la leucemia mieloide.
Palle, Josefine. „Optimizing Chemotherapy in Childhood Acute Myeloid Leukemia“. Doctoral thesis, Uppsala University, Department of Women's and Children's Health, 2008. http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-9189.
Despite major advances in our understanding of the biology of childhood acute myeloid leukemia (AML) and the development of new cytotoxic drugs, the prognosis of long-term survival is still only 60-65 %.
In the present research, we studied the pharmacokinetics of drugs used in the induction therapy of childhood AML and performed in vitro drug sensitivity testing of leukemic cells from children with AML.
The aims of the studies were to correlate the results of the analysis to biological and clinical parameters and to identify subgroups of AML with specific drug sensitivity profiles in order to better understand why treatment fails in some patients and how therapy may be improved.
Blood samples were analysed to study the pharmacokinetics of doxorubicin (n=41), etoposide (n=45) and 6-thioguanine (n=50). Doxorubicin plasma concentration and total body clearance were correlated to the effect of induction therapy, and doxorubicin plasma concentration was an independent factor for complete remission, both in univariate and multivariate analysis including sex, age, and white blood cell count at diagnosis. For etoposide and 6-thioguanine no correlation was found between pharmacokinetics and clinical effect. Children with Down syndrome (DS) tended to reach higher blood concentrations of etoposide and thioguanine nucleotides, indicating that dose reduction may be reasonable to reach the same drug exposure as in children without DS.
Leukemic cells from 201 children with newly diagnosed AML, 15 of whom had DS, were successfully analysed for in vitro drug sensitivity by the fluorometric microculture cytotoxicity assay (FMCA). We found that samples from children with DS were highly sensitive to most drugs used in AML treatment. In non-DS children, the t(9;11) samples were significantly more sensitive to cytarabine (p=0.03) and doxorubicin (p=0.035) than other samples. The findings might explain the very favorable outcome reported in children with DS and t(9;11)-positive AML. A specific drug resistance profile was found for several other genetic subgroups as well. A detailed study of MLL-rearranged leukemia showed that cellular drug sensitivity is correlated both to partner genes and cell lineage, findings that support the strategy of contemporary protocols to include high-dose cytarabine in the treatment of patients with MLL-rearrangement, both in AML and acute lymphoblastic leukemia (ALL).
Our results indicate that drug resistance and pharmacokinetic studies may yield important information regarding drug response in different sub-groups of childhood AML, helping us to optimize future chemotherapy in childhood AML.
Watson, Alexander Scarth. „Autophagy in hematopoiesis and acute myeloid leukemia“. Thesis, University of Oxford, 2014. http://ora.ox.ac.uk/objects/uuid:2e66c5c3-4774-44d1-8345-d0dc827da16d.
Bücher zum Thema "Myeloid leukemia":
Harry, Iland, Hertzberg Mark und Marlton Paula. Myeloid Leukemia. New Jersey: Humana Press, 2005. http://dx.doi.org/10.1385/1597450170.
Röllig, Christoph, und Gert J. Ossenkoppele, Hrsg. Acute Myeloid Leukemia. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-72676-8.
Hehlmann, Rüdiger, Hrsg. Chronic Myeloid Leukemia. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-71913-5.
Li, Shaoguang, und Haojian Zhang, Hrsg. Chronic Myeloid Leukemia. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-4011-0.
Hehlmann, Rüdiger, Hrsg. Chronic Myeloid Leukemia. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-33198-0.
Fortina, Paolo, Eric Londin, Jason Y. Park und Larry J. Kricka, Hrsg. Acute Myeloid Leukemia. New York, NY: Springer New York, 2017. http://dx.doi.org/10.1007/978-1-4939-7142-8.
E, Cortés F. Jorge, und Deininger Michael, Hrsg. Chronic myeloid leukemia. New York: Informa Healthcare, 2007.
Bain, Barbara J. Chronic myeloid leukaemias. Oxford: Clinical Pub., 2012.
Hughes, Timothy P., David M. Ross und Junia V. Melo. Handbook of Chronic Myeloid Leukemia. Cham: Springer International Publishing, 2014. http://dx.doi.org/10.1007/978-3-319-08350-6.
Harry, Iland, Hertzberg Mark und Marlton Paula, Hrsg. Myeloid leukemia: Methods and protocols. Totowa, N.J: Humana Press, 2006.
Buchteile zum Thema "Myeloid leukemia":
Voso, Maria Teresa, Eleonora De Bellis und Tiziana Ottone. „Diagnosis and Classification of AML: WHO 2016“. In Acute Myeloid Leukemia, 23–54. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-72676-8_2.
Kayser, Sabine, und Uwe Platzbecker. „Management of Acute Promyelocytic Leukemia“. In Acute Myeloid Leukemia, 177–97. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-72676-8_8.
Jaramillo, Sonia, und Richard F. Schlenk. „Treatment of Relapsed and Refractory AML: Intensive Approach in Fit Patients“. In Acute Myeloid Leukemia, 233–40. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-72676-8_11.
Bornhäuser, Martin. „Allogeneic Hematopoietic Cell Transplantation“. In Acute Myeloid Leukemia, 255–65. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-72676-8_13.
Itzykson, Raphael, Marco Cerrano und Jordi Esteve. „Prognostic Factors in AML“. In Acute Myeloid Leukemia, 127–75. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-72676-8_7.
Wierzbowska, Agnieszka, und Magdalena Czemerska. „Clinical Manifestation and Diagnostic Workup“. In Acute Myeloid Leukemia, 119–26. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-72676-8_6.
Sprute, Rosanne, und Oliver A. Cornely. „Special Clinical Scenarios: Infectious Complications and Prophylaxis“. In Acute Myeloid Leukemia, 285–92. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-72676-8_16.
Venditti, Adriano, Peter J. M. Valk, Nigel H. Russell und Sylvie D. Freeman. „Future Developments: Measurable Residual Disease“. In Acute Myeloid Leukemia, 317–37. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-72676-8_18.
Bug, Gesine, und Halvard Bonig. „Special Clinical Scenarios: Hyperleukocytosis“. In Acute Myeloid Leukemia, 267–73. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-72676-8_14.
Estey, Elihu. „Future Developments: Innovative Trial Design“. In Acute Myeloid Leukemia, 349–58. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-72676-8_20.
Konferenzberichte zum Thema "Myeloid leukemia":
DeMarco, B., M. O. Al-Qadi, S. S. Carson und S. Ghosh. „Leukemic Pleural Effusion in Acute Myeloid Leukemia“. In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a4863.
Rosenbluth, Michael J., Wilbur A. Lam und Daniel A. Fletcher. „Contribution of Cell Mechanics to Acute Leukemia“. In ASME 2004 International Mechanical Engineering Congress and Exposition. ASMEDC, 2004. http://dx.doi.org/10.1115/imece2004-59881.
Sultonova, Sherozakhon. „CLINICAL-HEMATOLOGICAL FEATURES OF CHRONIC MYELOID LEUKEMIA“. In RICERCHE SCIENTIFICHE E METODI DELLA LORO REALIZZAZIONE: ESPERIENZA MONDIALE E REALTÀ DOMESTICHE, Chair Din Mohammad, Khamid Karimov, Kodirjon Boboyev und Khamida Kazakbayeva. European Scientific Platform, 2021. http://dx.doi.org/10.36074/logos-26.11.2021.v3.22.
Verhagen, Han, Marjon Smit, David de Leeuw, Arjo Rutten, Mei-Ling Tsui, Fedor Denkers, Monique Terwijn et al. „Abstract 2339: IGFBP7 eradicates leukemic stem and progenitor cells in acute myeloid leukemia“. In Proceedings: AACR 106th Annual Meeting 2015; April 18-22, 2015; Philadelphia, PA. American Association for Cancer Research, 2015. http://dx.doi.org/10.1158/1538-7445.am2015-2339.
Shin, J. W., und D. J. Mooney. „Myeloid leukemia subtype-dependent sensitivity to matrix mechanics“. In 2014 40th Annual Northeast Bioengineering Conference (NEBEC). IEEE, 2014. http://dx.doi.org/10.1109/nebec.2014.6972939.
Dai, Aili, Chen Zhao, C. Cameron Yin, Ling Chen, Xiaoping Sun, Sanat Dave, Xiaoyan Huang, Yu H. Zhang, Xin Han und M. James You. „Abstract 170: Hypermethylation ofDBCCR1gene in acute myeloid leukemia“. In Proceedings: AACR 101st Annual Meeting 2010‐‐ Apr 17‐21, 2010; Washington, DC. American Association for Cancer Research, 2010. http://dx.doi.org/10.1158/1538-7445.am10-170.
Al-Qadi, M. O., M. Hunsucker und J. Akulian. „Acute Myeloid Leukemia Arising from Pleural Extramedullary Hematopoiesis“. In American Thoracic Society 2020 International Conference, May 15-20, 2020 - Philadelphia, PA. American Thoracic Society, 2020. http://dx.doi.org/10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6702.
Ramos, Doralina do Amaral Rabello, Vivian D'Afonseca da Silva Ferreira, Maria Gabriela Berzoti-Coelho, Sandra Mara Burin, Cíntia Leticia Magro, Maira da Costa Cacemiro, Belinda Pinto Simões, Felipe Saldanha-Araujo, Fabíola Attié Castro und Fábio Pittella-Silva. „Abstract 366: Association ofMLL2/KMT2DandMLL3/KMT2Cwith chronic myeloid leukemia“. In Proceedings: AACR Annual Meeting 2018; April 14-18, 2018; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-366.
Adi, Y. A., F. Adi-Kusumo, L. Aryati und M. S. Hardianti. „Modelling inhibition of AKT phosphorylation in acute myeloid leukemia“. In THE 2016 CONFERENCE ON FUNDAMENTAL AND APPLIED SCIENCE FOR ADVANCED TECHNOLOGY (CONFAST 2016): Proceeding of ConFAST 2016 Conference Series: International Conference on Physics and Applied Physics Research (ICPR 2016), International Conference on Industrial Biology (ICIBio 2016), and International Conference on Information System and Applied Mathematics (ICIAMath 2016). Author(s), 2016. http://dx.doi.org/10.1063/1.4953987.
de Leeuw, Dave C., Willemijn van den Ancker, Fedor Denkers, Rene X. Menezes, Theresia M. Westers, Gert J. Ossenkoppele, Arjan A. van de Loosdrecht und Linda Smit. „Abstract LB-246: MicroRNA profiling can classify acute leukemias of ambiguous lineage as either acute myeloid leukemia or acute lymphoid leukemia.“ In Proceedings: AACR 104th Annual Meeting 2013; Apr 6-10, 2013; Washington, DC. American Association for Cancer Research, 2013. http://dx.doi.org/10.1158/1538-7445.am2013-lb-246.
Berichte der Organisationen zum Thema "Myeloid leukemia":
Muller-Sieburg, Christa. Myeloid-Biased Stem Cells as Potential Targets for Chronic Myelogeneous Leukemia. Fort Belvoir, VA: Defense Technical Information Center, September 2005. http://dx.doi.org/10.21236/ada447669.
FLORIDA UNIV GAINESVILLE. Dissection of the Pathogenesis of Neurofibromatosis Type 1-Associated myeloid Leukemia. Fort Belvoir, VA: Defense Technical Information Center, Oktober 1998. http://dx.doi.org/10.21236/ada359875.
Brannan, Camilynn I. Dissection of the Pathogenesis of Neurofibromatosis Type 1-Associated Myeloid Leukemia. Fort Belvoir, VA: Defense Technical Information Center, Oktober 1999. http://dx.doi.org/10.21236/ada391284.
Brannan, Camilynn I. Dissection of the Pathogenesis of Neurofibromatosis Type 1-Associated Myeloid Leukemia. Fort Belvoir, VA: Defense Technical Information Center, Oktober 2000. http://dx.doi.org/10.21236/ada392474.
Zhang, Chengcheng. Dissecting the Role of IGFBP-2 in Development of Acute Myeloid Leukemia. Fort Belvoir, VA: Defense Technical Information Center, Juni 2011. http://dx.doi.org/10.21236/ada555017.
Zhang, Dong-Er. Protein ISG15 Modification in the Development and the Treatment of Chronic Myeloid Leukemia. Fort Belvoir, VA: Defense Technical Information Center, Juni 2007. http://dx.doi.org/10.21236/ada482354.
Sorror, Mohamed L., Barry E. Storer und Elihu H. Estey. Comparing Hematopoietic Cell Transplant versus Other Treatments for Adults with Acute Myeloid Leukemia. Patient-Centered Outcomes Research Institute (PCORI), Januar 2021. http://dx.doi.org/10.25302/01.2021.ce.13047451.
Tremblay, Michel. Contribution of Protein Tyrosine Phosphateses to the Ontogeny and Progression of Chronic Myeloid Leukemia. Fort Belvoir, VA: Defense Technical Information Center, April 2006. http://dx.doi.org/10.21236/ada462811.
Gong, Jun. Diminishing oncometabolic havoc: Approved IDH1 and IDH2 inhibitors in relapsed or refractory acute myeloid leukemia. Science Repository OU, Dezember 2018. http://dx.doi.org/10.31487/j.aco.2018.01.004.
Getz, Kelly D., Julia E. Szymczak, Farah Contractor, Brian T. Fisher und Richard Aplenc. Comparing Chemotherapy Recovery at Home versus in the Hospital for Children with Acute Myeloid Leukemia. Patient-Centered Outcomes Research Institute (PCORI), Januar 2021. http://dx.doi.org/10.25302/01.2021.cer.140922827.